医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Vietnam Ministry of Health and Quintiles Collaborate to Advance Clinical Trial Excellence

2013年11月20日 AM11:25
このエントリーをはてなブックマークに追加


 

SINGAPORE

The Vietnam Ministry of Health’s Administration of Science, Technology and Training (ASTT) has signed an agreement with Quintiles to enhance clinical research in this growing nation of 90 million people, Quintiles announced today.

This collaboration marks a new stage in the ministry’s efforts to support the development of new, better therapies for diseases that afflict the populations of Vietnam and Southeast Asia, said ASTT Director Prof. Nguyen Cong Khan, M.D., Ph.D.

“Quintiles knows how to conduct clinical research to global standards and its experts understand Asia and Vietnam,” Prof. Khan said. “By sharing their knowledge and insights, Quintiles can help us develop and execute a long-term plan for improving the quality, scope and breadth of clinical research in Vietnam.”

Under the two-year agreement, Quintiles and ASTT will collaborate in forming a larger working group to address a variety of topics, including improved processes for trial management; development of streamlined processes to improve trial efficiency and quality; and training for investigators and ethics committees.

“We’ve been working with the ministry to provide investigator training and site development since first establishing a presence in Vietnam in 2005,” said Ross Horsburgh, M.D., who leads Quintiles’ operations in Southeast Asia, Taiwan, South Korea, Australia and New Zealand. “This agreement deepens our commitment to developing medicines here to fight tropical and infection diseases and other conditions that afflict populations in Vietnam and Southeast Asia.”

Quintiles Vietnam LLC has offices in Ho Chi Minh City and Hanoi.

About Quintiles

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 28,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.

Click here to subscribe to Mobile Alerts for Quintiles.

CONTACT

Quintiles
Jessie Lee, Media Relations, +65.6602.1576 (office)
+65.8181.3805 (mobile)
jessie.lee@quintiles.com
or
Karl
Deonanan, Investor Relations, +1.919.998.2789
InvestorRelations@quintiles.com
www.quintiles.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 2018年江戸川NICHE賞は幹細胞発見の功績によりジェームズ・ティル教授に授与へ
  • 武田薬品工業によるシャイアーの買収案を日本の公正取引委員会が承認
  • 武田拟收购Shire plc获得日本公平交易委员会批准
  • James Till教授因干细胞发现而荣获2018年度江户川Niche奖
  • Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis